Safety and effectiveness of the combination of systemic gemcitabine and intralesional brentuximab vedotin in tumor-stage mycosis fungoides

Int J Dermatol. 2024 Jun;63(6):828-830. doi: 10.1111/ijd.17107. Epub 2024 Feb 28.
No abstract available

Keywords: brentuximab vedotin; cutaneous T‐cell lymphoma; gemcitabine; mycosis fungoides; treatment of lymphoma.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols* / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols* / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Brentuximab Vedotin* / administration & dosage
  • Deoxycytidine* / administration & dosage
  • Deoxycytidine* / analogs & derivatives
  • Gemcitabine*
  • Humans
  • Immunoconjugates / administration & dosage
  • Immunoconjugates / adverse effects
  • Injections, Intralesional
  • Mycosis Fungoides* / drug therapy
  • Mycosis Fungoides* / pathology
  • Neoplasm Staging
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / pathology
  • Treatment Outcome

Substances

  • Brentuximab Vedotin
  • Deoxycytidine
  • Gemcitabine
  • Immunoconjugates